Detected ·

Soufflé Therapeutics

$135M—

Soufflé Therapeutics closed an oversubscribed $135M Series B led by Juvia Group, with participation from TCGX, BB Biotech, Fidelity, ARCH Venture Partners, Bessemer, Amgen, and others, to advance its REMEDY™ cell-specific delivery platform and pipeline programs.

Amount
$135 000 000 USD
Stage
—
Event
Funding round
Detected
2026-10-14 04:03:35 UTC
Signal ID
28366819-504f-4605-8577-2f743bdcc55a

As the API returns it

{
  "id": "28366819-504f-4605-8577-2f743bdcc55a",
  "created_at": "2026-10-14T04:03:35.601671Z",
  "company_name": "Soufflé Therapeutics",
  "company_website_url": "www.souffletx.com",
  "company_linkedin_url": "https://www.linkedin.com/company/souffletherapeutics",
  "event_type": "funding",
  "funding_amount": 135000000,
  "funding_currency": "USD",
  "funding_stage": null,
  "message": "*Soufflé Therapeutics closed an oversubscribed $135M Series B led by Juvia Group, with participation from TCGX, BB Biotech, Fidelity, ARCH Venture Partners, Bessemer, Amgen, and others, to advance its REMEDY™ cell-specific delivery platform and pipeline programs.*"
}

Latest rounds